Doms № 4 -2022

Modern approaches to treatment of obesity

Cherenko M. S.

Abstract

Obesity is a chronic disease, spread of which is constantly increasing among adults, adolescents and children throughout the world. Obesity is a global epidemic. It is impossible to underestimate the risks of obesity. It has been statistically proven that it is associated with an increase in mortality and the risk of various diseases, primarily metabolic and cardiovascular, as well as oncological and psychological. Obesity reduces life expectancy by 0.8–13.7 years. In the US, a third of the adult population is overweight, and another third is obese. Statistics in the world are also disappointing – up to 650 million people are obese. It is believed that by 2030, the number of patients with this disease will exceed 44 %. Many studies are currently devoted studying the causes of obesity. Many genes are known to be associated with the development of obesity, but almost always a number of factors will influence development of this disease: among them of course eating habits and lifestyle. The question of the presence of certain factors often arises in the course of obesity and which endocrine problems that could lead to to weight gain. The article analyses existing data on factors leading to the development of obesity.

Key words: obesity, metabolic diseases, cardiovascular diseases, epidemic factors.

References

  1. Camilleri M., Acosta A. Combination Therapies for Obesity // Metabolic syndrome and related disorders. – 2018. – V. 16, N.8. – P. 390-394.
  2. Mastrandrea L.D., Witten L., Carlsson Petri K.C. et al. Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics // Pediatric Obesity. – 2019. – V. 14. e12495. – 9 p. – https://doi.org/10.1111/ijpo.12495.
  3. Gorgojo-Martínez J.J., Basagoiti-Carreño B., Sanz-Velasco A. et al. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study // Int J Clin Pract. – 2019. – V. 73, N. 11. doi: 10.1111/ijcp.13399.
  4. Pilitsi E., Farr O.M., Polyzos S.A. et al. Pharmacotherapy of obesity: Available medications and drugs under investigation // Metabolism. – 2019. – V. 92. – P. 170-192. doi: 10.1016/j.metabol.2018.10.010.
  5. Mehta A., Marso S.P., Neeland I. J. Liraglutide for weight management: a critical review of the evidence // Obesity science and medicine. – 2016. – 12 p. – https://doi.org/10.1002/osp4.84.
  6. Kelly A.S., Auerbach P., Margarita Barrientos-Perez M. et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity // N Engl J Med. – 2020. – V. 382, N. 22. – P. 2117-2128. doi: 10.1056/NEJMoa1916038.
  7. Ladenheim E.E. Liraglutide and obesity: a review of the data so far // Drug Des Devel Ther. – 2015. – V. 9. – P. 1867-75. doi: 10.2147/DDDT.S58459.
  8. Lin C-H., Shao L., Zhang Y-M. et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity // Expert Opin Pharmacother. – 2020. – V. 21, N. 3. – P. 275-285. – doi: 10.1080/14656566.2019.1695779.
  9. O’Neil P.M., Birkenfeld A. L., Barbara McGowan B. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial // Lancet. – 2018. – V. 392(10148). – P. 637-649. – doi: 10.1016/S0140-6736(18)31773-2.
  10. Gadde K.M., Martin C.K., Berthoud H-R., Heymsfield S.B. Obesity: Pathophysiology and Management // J Am Coll Cardiol. – 2018. – V. 71, N. 1. – P. 69-84. – doi: 10.1016/j.jacc.2017.11.011.
  11. Pastor R., Tur J.A. Liraglutide for the Treatment of Obesity: Analyzing Published Reviews // Curr Pharm Des. – 2019. – V. 25, N. 15. – P. 1783-1790. – doi: 10.2174/1381612825666190701155737.
  12. Knudsen L.B., Lau J. The Discovery and Development of Liraglutide and Semaglutide // Front Endocrinol (Lausanne). – 2019. – V. 10. – P. 155. – doi: 10.3389/fendo.2019.00155.
  13. Cena H., Chiovato L., Nappi R.E. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists // J Clin Endocrinol Metab. – 2020. – V. 105, N. 8. – e2695-e2709. – doi: 10.1210/clinem/dgaa285.
  14. Wadden T.A., Tronieri J.S., Sugimoto D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial // Obesity (Silver Spring). – 2020. – V. 28, N. 3. – P. 529-536. – doi: 10.1002/oby.22726.
  15. Booth A., Magnuson A., Fouts J., Foster M.T. Adipose tissue: an endocrine organ playing a role in metabolic regulation // Horm Mol Biol Clin Invest. – – 18 p. – DOI 10.1515/hmbci-2015-0073.
  16. Wilding J.P.H. Endocrine testing in obesity // Eur J Endo. – 2020. – V. 182. P. C13-C15. – https://doi.org/10.1530/EJE-20-0099.
  17. Bray G.A., Kim K.K., Wilding JPH & World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation // Obesity Reviews. – 2017. – V. 18. – P. 715–723. – https://doi.org/10.1111/obr.12551.
  18. van Hulsteijn L.T., Pasquali R., Casanueva F. et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis // Eur J Endo. – 2020. – V. 182. – P. 11-21. – https://doi.org/10.1530/EJE-19-0666.
  19. Pasquali R., Casanueva F., Haluzik M. et al. European Society of Endocrinology Clinical Practice Guideline: endocrine work-up in obesity // Eur J Endo. – 2020. – V. 182. – P. G1-G32. – https://doi.org/10.1530/EJE-19-0893.
  20. Mechanick J.I., Hurley D.L., Garvey W.T. Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement // Endocr Pract. – 2017. – V. 23, N. 3. – P. 372-378.
  21. Buch A., Marcus Y., Shefer G., Zimmet P., Stern N. Approach to Obesity in the Older Population // J Clin Endocrinol Metab. – 2021. – V. 106, N. 9.  2788-2805.  – doi: 10.1210/clinem/dgab359.
  22. Janković D., Wolf, AnderwaldC.H. et al. Prevalence of endocrine disorders in morbidly obese patients and the effects of bariatric surgery on endocrine and metabolic parameters // Obesity Surgery. – 2012. – V. 22. – P. 62-69. – https://doi.org/10.1007/s11695-011- 0545-4.
  23. Wang F.F. et al. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network metaanalysis. // Obes Rev – – V. 19(10). – P.1424-1445. – doi: 10.1111/obr.12720.
  24. Frøssing S., Nylander M., Chabanova E. et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial // Diabetes Obes Metab. – 2018. – V. 20, N. 1. – P. 215-218.
  25. Iepsen E.W. et al. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist // Cell Metab. 2018. – V. 28, N. 1. – P. 23-32.